source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...Endpoints · 3mo ago↗ source
- Roche to acquire digital pathology firm PathAI in deal potentially worth over $1BRoche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.BioPharma Dive · 3mo ago↗ source
- STAT+: More political interference at the FDA?A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.STAT · 3mo ago↗ source